EBNA2 and Notch signalling in Epstein-Barr virus mediated immortalization of B lymphocytes

Seminars in Cancer Biology

Volumn 11, Issue 6, 2001, Pages 423-434

  Zimber Strobl, Ursula ^a   Strobl, Lothar J ^a  

^a UNIVERSITY OF COLOGNE   (Germany)

Author keywords

B lymphocytes; EBNA2; Epstein Barr virus; Notch; RBP J

Indexed keywords

ANKYRIN; CELL PROTEIN; EPSTEIN BARR VIRUS ANTIGEN; EPSTEIN BARR VIRUS ENCODED NUCLEAR ANTIGEN 2; NOTCH RECEPTOR; PROTEIN RBP J; UNCLASSIFIED DRUG;

B LYMPHOCYTE; B LYMPHOCYTE DIFFERENTIATION; CELL IMMORTALIZATION; EPSTEIN BARR VIRUS; GENE DELETION; GENE EXPRESSION REGULATION; GENE FUNCTION; GENETIC ANALYSIS; HUMAN; LYMPHOMA; NONHUMAN; PROMOTER REGION; PROTEIN PROTEIN INTERACTION; PROTEIN STRUCTURE; REVIEW; SIGNAL TRANSDUCTION; VIRAL GENETICS; VIRUS CARCINOGENESIS;

EID: 0035200379     PISSN: 1044579X     EISSN: None     Source Type: Journal    
DOI: 10.1006/scbi.2001.0409     Document Type: Article

References (143)

1. Epstein-Barr virus
2. EBV persistence in memory B cells in vivo
3. Epstein-Barr virus and its replication
4. Immunofluorescence and herpes-type virus particles in the P3HR-1 Burkitt lymphoma cell line
5. Differences between laboratory strains of Epstein-Barr virus based on immortalization, abortive infection, and interference
6. Deletion of the nontransforming Epstein-Barr virus strain P3HR-1 causes fusion of the large internal repeat to the DSL region
7. U2 region of Epstein-Barr virus DNA may encode Epstein-Barr nuclear antigen 2
8. Identification of the coding region for a second Epstein-Barr virus nuclear antigen (EBNA 2) by transfection of cloned DNA fragments
9. A second nuclear protein is encoded by Epstein-Barr virus in latent infection
10. The Epstein-Barr virus determined nuclear antigen is composed of at least three different antigens
11. Genetic analysis of immortalizing functions of Epstein-Barr virus in human B lymphocytes
12. Epstein-Barr virus nuclear protein 2 is a key determinant of lymphocyte transformation
13. B-cell proliferation and induction of early G1-regulating proteins by Epstein-Barr virus mutants conditional for EBNA2
14. A putative transforming gene of Jijoye virus differs from that of Epstein-Barr virus prototypes
15. EBNA-2 of herpesvirus papio diverges significantly from the type A and type B EBNA-2 proteins of Epstein-Barr virus but retains an efficient transactivation domain with a conserved hydrophobic motif
16. Epstein-Barr virus nuclear protein 2 mutations define essential domains for transformation and transactivation
17. The N-terminal half of EBNA2, except for seven prolines, is not essential for primary B-lymphocyte growth transformation
18. Residues 231 to 280 of the Epstein-Barr virus nuclear protein 2 are not essential for primary B-lymphocyte growth transformation
19. An Epstein-Barr virus nuclear protein 2 domain essential for transformation is a direct transcriptional activator
20. Epstein-Barr virus latent gene expression during the initiation of B cell immortalization
21. Influence of Burkitt's lymphoma and primary B cells on latent gene expression by the nonimmortalizing P3J-HR-1 strain of Epstein-Barr virus
22. EBNA-2 and EBNA-LP cooperate to cause G0 to G1 transition during immortalization of resting human B lymphocytes by Epstein-Barr virus
23. Promoter switching in Epstein-Barr virus during the initial stages of infection of B lymphocytes
24. EBNA-2 transactivates a lymphoid-specific enhancer in the BamHI C promoter of Epstein-Barr virus
25. Epstein-Barr virus nuclear antigen 2 induces expression of the virus-encoded latent membrane protein
26. Epstein-Barr virus-encoded nuclear antigen 2 activates the viral latent membrane protein promoter by modulating the activity of a negative regulatory element
27. Epstein-Barr virus nuclear antigen 2 transactivates latent membrane protein LMP1
28. Epstein-Barr virus nuclear antigen 2 activates transcription of the terminal protein gene
29. Identification and characterization of an Epstein-Barr virus nuclear antigen 2-responsive cis element in the bidirectional promoter region of latent membrane protein and terminal protein 2 genes
30. Epstein-Barr virus (EBV) induces expression of B-cell activation markers on in vitro infection of EBV-negative B-lymphoma cells
31. Epstein-Barr virus nuclear antigen 2 specifically induces expression of the B-cell activation antigen CD23
32. Stable transfection of Epstein-Barr virus (EBV) nuclear antigen 2 in lymphoma cells containing the EBV P3HR1 genome induces expression of B-cell activation molecules CD21 and CD23
33. The level of c-fgr RNA is increased by EBNA-2, an Epstein-Barr virus gene required for B-cell immortalization
34. Regulation of c-fgr proto-oncogene expression in Epstein-Barr virus infected B-cell lines
35. Expression of the chemokine receptor BLR2/EBI1 is specifically transactivated by Epstein-Barr virus nuclear antigen 2
36. The proto-oncogene c-myc is a direct target gene of Epstein-Barr virus nuclear antigen 2
37. Epstein-Barr virus nuclear antigen 2 is a transcriptional suppressor of the immunoglobulin mu gene: Implications for the expression of the translocated c-myc gene in Burkitt's lymphoma cells
38. The Epstein-Barr virus nuclear antigen 2 interacts with an EBNA2 responsive cis-element of the terminal protein 1 gene promoter
39. The Spi-1/PU.1 and Spi-B ets family transcription factors and the recombination signal binding protein RBP-J kappa interact with an Epstein-Barr virus nuclear antigen 2 responsive cis-element
40. EBNA-2 upregulation of Epstein-Barr virus latency promoters and the cellular CD23 promoter utilizes a common targeting intermediate, CBF1
41. Mediation of Epstein-Barr virus EBNA2 transactivation by recombination signal-binding protein J kappa
42. The Epstein-Barr virus nuclear antigen 2 transactivator is directed to response elements by the J kappa recombination signal binding protein
43. The human J kappa recombination signal sequence binding protein (RBP-J kappa) targets the Epstein-Barr virus EBNA2 protein to its DNA responsive elements
44. Epstein-Barr virus nuclear antigen 2 exerts its transactivating function through interaction with recombination signal binding protein RBP-J kappa, the homologue of Drosophila Suppressor of Hairless
45. Purification and characterization of a protein that binds to the recombination signal sequence of the immunoglobulin J kappa segment
46. A protein binding to the J kappa recombination sequence of immunoglobulin genes contains a sequence related to the integrase motif
47. Notch signaling: Cell fate control and signal integration in development
48. Notch1 is essential for postimplantation development in mice
49. Mutation in ankyrin repeats of the mouse Notch2 gene induces early embryonic lethality
50. An activated Notch suppresses neurogenesis and myogenesis but not gliogenesis in mammalian cells
51. The intracellular domain of mouse Notch: A constitutively activated repressor of myogenesis directed at the basic helix-loop-helix region of MyoD
52. Notch signalling controls pancreatic cell differentiation
53. Inhibition of granulocytic differentiation by mNotch1
54. Notch signalling via RBP-J promotes myeloid differentiation
55. Notch1 expression in early lymphopoiesis influences B versus T lineage determination
56. Deficient T cell fate specification in mice with an induced inactivation of Notch1
57. The ins and outs of notch signaling
58. Roles of the ankyrin repeats and C-terminal region of the mouse notch1 intracellular region
59. Neoplastic transformation by Notch is independent of transcriptional activation by RBP-J signalling
60. LIN-12/Notch signaling: Lessons from worms and flies
61. Molecular cloning of delta-4, a new mouse and human Notch ligand
62. Intracellular cleavage of Notch leads to a heterodimeric receptor on the plasma membrane
63. The Notch1 receptor is cleaved constitutively by a furin-like convertase
64. A ligand-induced extracellular cleavage regulates gamma-secretase-like proteolytic activation of Notch1
65. A novel proteolytic cleavage involved in Notch signaling: The role of the disintegrin-metalloprotease TACE
66. A presenilin-1-dependent gamma-secretase-like protease mediates release of Notch intracellular domain
67. Presenilin is required for activity and nuclear access of Notch in Drosophila
68. Two transmembrane aspartates in presenilin-1 required for presenilin endoproteolysis and gamma-secretase activity
69. Signalling downstream of activated mammalian Notch
70. Signal transduction by activated mNotch: Importance of proteolytic processing and its regulation by the extracellular domain
71. Nuclear access and action of notch in vivo
72. Notch-1 signalling requires ligand-induced proteolytic release of intracellular domain
73. Indirect evidence for delta-dependent intracellular processing of notch in Drosophila embryos
74. Ligand-induced cleavage and regulation of nuclear entry of Notch in Drosophila melanogaster embryos
75. Structure, chromosomal locus, and promoter of mouse Hes2 gene, a homologue of Drosophila hairy and Enhancer of split
76. Comparative analysis of the human and mouse Hey1 promoter: Hey genes are new Notch target genes
77. Regulation of the ERBB-2 promoter by RBPJkappa and NOTCH
78. NF-kappaB2 is a putative target gene of activated Notch-1 via RBP-Jkappa
79. Members of the HRT family of basic helix-loop-helix proteins act as transcriptional repressors downstream of Notch signaling
80. A histone deacetylase corepressor complex regulates the Notch signal transduction pathway
81. CIR, a corepressor linking the DNA binding factor CBF1 to the histone deacetylase complex
82. The mammalian transcriptional repressor RBP (CBF1) targets TFIID and TFIIA to prevent activated transcription
83. Masking of the CBF1/RBPJ kappa transcriptional repression domain by Epstein-Barr virus EBNA2
84. Genetic and biochemical evidence that EBNA 2 interaction with a 63-kDa cellular GTC-binding protein is essential for B lymphocyte growth transformation by EBV
85. Physical interaction between a novel domain of the receptor Notch and the transcription factor RBP-J kappa/Su(H)
86. Involvement of RBP-J in biological functions of mouse Notch1 and its derivatives
87. Oncogenic forms of NOTCH1 lacking either the primary binding site for RBP-Jkappa or nuclear localization sequences retain the ability to associate with RBP-Jkappa and activate transcription
88. SKIP, a CBF1-associated protein, interacts with the ankyrin repeat domain of NotchIC to facilitate NotchIC function
89. The 62-and 80-kDa subunits of transcription factor IIH mediate the interaction with Epstein-Barr virus nuclear protein 2
90. The Epstein-Barr virus nuclear protein 2 acidic domain can interact with TFIIB, TAF40, and RPA70 but not with TATA-binding protein
91. The Epstein-Barr virus nuclear protein 2 acidic domain forms a complex with a novel cellular coactivator that can interact with TFIIE
92. Epstein-Barr virus nuclear protein 2 interacts with p300, CBP, and PCAF histone acetyltransferases in activation of the LMP1 promoter
93. Epstein-Barr virus leader protein enhances EBNA-2-mediated transactivation of latent membrane protein 1 expression: A role for the W1W2 repeat domain
94. Epstein-Barr virus nuclear protein LP stimulates EBNA-2 acidic domain-mediated transcriptional activation
95. Epstein-Barr virus nuclear protein 2 (EBNA2) binds to a component of the human SNF-SWI complex, hSNF5/Inil
96. Promoter-specific targeting of human SWI-SNF complex by Epstein-Barr virus nuclear protein 2
97. Functional interaction between the mouse notch1 intracellular region and histone acetyltransferases PCAF and GCN5
98. MAML1, a human homologue of Drosophila mastermind, is a transcriptional co-activator for NOTCH receptors
99. EBNA-2 and EBNA-3C extensively and mutually exclusively associate with RBPJkappa in Epstein-Barr virus-transformed B lymphocytes
100. Epstein-Barr virus nuclear protein 3C modulates transcription through interaction with the sequence-specific DNA-binding protein J kappa
101. Epstein-Barr virus EBNA3A and EBNA3C proteins both repress RBP-J kappa-EBNA2-activated transcription by inhibiting the binding of RBP-J kappa to DNA
102. A conserved domain of the Epstein-Barr virus nuclear antigens 3A and 3C binds to a discrete domain of Jkappa
103. Epstein-Barr virus nuclear antigen 3C interacts with histone deacetylase to repress transcription
104. LlM protein KyoT2 negatively regulates transcription by association with the RBP-J DNA-binding protein
105. Epstein-Barr virus nuclear protein 2 transactivates a cis-acting CD23 DNA element
106. Crucial sequences within the Epstein-Barr virus TP1 promoter for EBNA2-mediated transactivation and interaction of EBNA2 with its responsive element
107. Epstein-Barr virus nuclear protein 2 transactivation of the latent membrane protein 1 promoter is mediated by J kappa and PU.1
108. PU box-binding transcription factors and a POU domain protein cooperate in the Epstein-Barr virus (EBV) nuclear antigen 2-induced transactivation of the EBV latent membrane protein 1 promoter
109. Regulation of Epstein-Barr virus C promoter by AVFI and the cyclic AMP/Protein kinase A signaling pathway
110. Activated mouse Notch1 transactivates Epstein-Barr virus nuclear antigen 2-regulated viral promoters
111. TAN-1, the human homolog of the Drosophila notch gene, is broken by chromosomal translocations in T lymphoblastic neoplasms
112. Exclusive development of T cell neoplasms in mice transplanted with bone marrow expressing activated Notch alleles
113. Transduction of Notch2 in feline leukemia virus-induced thymic lymphoma
114. Constitutive activation of NF-kappaB and T-cell leukemia/lymphoma in Notch3 transgenic mice
115. Expression of an activated Notch-related int-3 transgene interferes with cell differentiation and induces neoplastic transformation in mammary and salivary glands
116. The mouse mammary tumor associated gene INT3 is a unique member of the NOTCH gene family (NOTCH4)
117. Frequent provirus insertional mutagenesis of Notch1 in thymomas of MMTVD/myc transgenic mice suggests a collaboration of c-myc and Notch1 for oncogenesis
118. Neoplastic transformation by truncated alleles of human NOTCH1/TAN1 and NOTCH2
119. Neoplastic transformation by Notch requires nuclear localization
120. Activation of the Notch-regulated transcription factor CBF1/RBP-Jkappa through the 13SE1A oncoprotein
121. Essential roles for ankyrin repeat and transactivation domains in induction of T-cell leukemia by notch1
122. The N- and C-terminal regions of RBP-J interact with the ankyrin repeats of Notch1 RAMIC to activate transcription
123. Activated Notch1 modulates gene expression in B cells similarly to Epstein-Barr viral nuclear antigen 2
124. Notch signaling suppresses IgH gene expression in chicken B cells: Implication in spatially restricted expression of Serrate2/Notch1 in the bursa of Fabricius
125. Activated Notch1 can transiently substitute for EBNA2 in the maintenance of proliferation of LMP1-expressing immortalized B cells
126. An activated form of Notch influences the choice between CD4 and CD8 T cell lineages
127. Notch activity influences the alphabeta versus gammadelta T cell lineage decision
128. Notch1 signaling promotes the maturation of CD4 and CD8 SP thymocytes
129. Inactivation of Notch 1 in immature thymocytes does not perturb CD4 or CD8T cell development
130. Microenvironmental influences on human B-cell development
131. Notch2: A second mammalian Notch gene
132. Rel/NF-kappaB can trigger the Notch signaling pathway by inducing the expression of Jagged1, a ligand for Notch receptors
133. The expression pattern of Epstein-Barr virus latent genes in vivo is dependent upon the differentiation stage of the infected B cell
134. Mimicry of CD40 signals by Epstein-Barr virus LMP1 in B lymphocyte responses
135. Latent membrane protein 1 of Epstein-Barr virus mimics a constitutively active receptor molecule
136. Epstein-Barr virus LMP2A drives B cell development and survival in the absence of normal B cell receptor signals
137. Restricted Epstein-Barr virus protein expression in Burkitt lymphoma is due to a different Epstein-Barr nuclear antigen 1 transcriptional initiation site
138. Linkage between STAT regulation and Epstein-Barr virus gene expression in tumors
139. Identification of target antigens for the human cytotoxic T cell response to Epstein-Barr virus (EBV): Implications for the immune control of EBV-positive malignancies
140. Functional replacement of the intracellular region of the Notch1 receptor by Epstein-Barr virus nuclear antigen 2
141. Delta-induced Notch signaling mediated by RBP-J inhibits MyoD expression and myogenesis
142. Notch as a mediator of cell fate determination in hematopoiesis: Evidence and speculation
143. Notch and the immune system